Skip to main content
Colorado General AssemblyToggle Main Menu
Agency NameToggle Agency Menu

Supplemental Payment Office-administered Drugs Medicaid

Concerning a supplemental state payment relating to certain office-administered oncology-related drugs for qualified providers under the medical assistance program who experienced a reduction in reimbursement payments in the 2017-18 state fiscal year as a result of the implementation of the federal final rules for covered outpatient drugs, and, in connection therewith, making an appropriation.
2018 Regular Session
Health Care & Health Insurance
Bill Summary

Medicaid - office-administered oncology drugs - providers - supplemental payment - state-only money - appropriation. The act authorizes a supplemental payment of state-only money to providers under the medicaid program of certain office-administered drugs relating to oncology who experienced a decrease in aggregate reimbursements in the 2017-18 fiscal year as a result of the implementation of the federal department of health and human services final rule for covered outpatient drugs, 81 FR 5169, published in the federal register on February 1, 2016.

The act directs the department of health care policy and financing (department) to distribute a supplemental payment to qualified providers, as defined in the act, and includes provisions for determining the amount of each qualified provider's supplemental payment. The act authorizes the medical services board to adopt rules as necessary.

$754,000 of general fund money is appropriated to the department for the supplemental payment to qualified providers.

(Note: This summary applies to this bill as enacted.)


Became Law


Bill Text

  • All Versions (7 )
    Date Bill Type Documents
    04/23/2018 Signed Act PDF
    04/16/2018 Final Act PDF
    04/05/2018 Rerevised PDF
    04/04/2018 Revised PDF
    03/29/2018 Reengrossed PDF
    03/28/2018 Engrossed PDF
    03/26/2018 Introduced PDF

The effective date for bills enacted without a safety clause is August 7, 2024, if the General Assembly adjourns sine die on May 8, 2024, unless otherwise specified. Details